在新的囊性纤维化治疗中,肥胖是问题吗?
Marta Solís-García1, Marta María García-Clemente2,3, Claudia Janeth Madrid-Carbajal3
1Servicio de Neumología, Hospital Universitario La Princesa, 28006 Madrid, Spain.
Nutrients
|September 28, 2024
概括
新的囊性纤维化 (CF) 治疗导致患者显著增加体重,增加超重和肥胖风险. 那些基线BMI较低,肺功能较差的人在CFTR调节器治疗中体重增加最为显著.
科学领域:
- 医学科学 医学科学 医学科学
- 肺部病理学 肺部病理学
- 遗传学 遗传学 是一个
背景情况:
- 营养不良是囊性纤维化 (CF) 患者的一个历史性问题.
- 新兴的CFTR调节器疗法促进体重增加,造成超重和肥胖的风险.
研究的目的:
- 在三重疗法 (elexacaftor/tezacaftor/ivacaftor) 一年后分析身体质量指数 (BMI) 的变化.
- 在接受三重治疗的CF患者中确定与体重增加相关的因素.
主要方法:
- 对108名CF患者 (≥18岁) 进行了前性,观察性,纵向性,多中心的研究,这些患者接受了≥1年的三重治疗.
- 收集了人口统计,人体测量,肺功能和恶化的数据,比较治疗前和治疗后的一年.
- 利用混合效应模型来分析BMI演变和相关因素.
主要成果:
- 平均BMI显著增加,从21.9公斤/平方米增加到23.0公斤/平方米 (p < 0.0001).
- 体重不足患者的比例下降 (9.3%至1.9%),而超重/肥胖患者的比例增加 (8.3%至22.9%).
- 观察到肺功能显著改善 (FEV1%增加) 和恶化的减少.
结论:
- 在CF患者的三重疗法导致显著的体重增加和超重个体的患病率增加.
- 更大的体重增加与较低的基线BMI,较差的肺功能和治疗前更高的恶化率有关.
相关概念视频
01:24Cystic Fibrosis: Management
144
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
144
01:23Cystic Fibrosis: Pathogenesis
194
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
194
01:29Chronic Pancreatitis II: Collaborative Care
70
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
70
01:21Drugs for Treatment of Constipation-Predominant IBS
140
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
140
01:24Obesity
392
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
392
01:22Heart Failure VI: Adjunct Therapies
5
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
5